JP2018533596A5 - - Google Patents

Info

Publication number

JP2018533596A5

JP2018533596A5 JP2018523814A JP2018523814A JP2018533596A5 JP 2018533596 A5 JP2018533596 A5 JP 2018533596A5 JP 2018523814 A JP2018523814 A JP 2018523814A JP 2018523814 A JP2018523814 A JP 2018523814A JP 2018533596 A5 JP2018533596 A5 JP 2018533596A5

Authority

JP

Japan

Prior art keywords

modified solid

microparticle

solid aggregated

microparticles

poly

Prior art date

2016-11-11

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 239000002245 particle Substances 0.000 claims description 5
• 230000002776 aggregation Effects 0.000 claims description 4
• 238000004220 aggregation Methods 0.000 claims description 4
• 238000000034 method Methods 0.000 claims description 3
• YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 3
• 239000011859 microparticle Substances 0.000 claims 52
• 239000007787 solid Substances 0.000 claims 44
• 239000003814 drug Substances 0.000 claims 13
• 229940124597 therapeutic agent Drugs 0.000 claims 13
• 229920002988 biodegradable polymer Polymers 0.000 claims 12
• 239000004621 biodegradable polymer Substances 0.000 claims 12
• 230000004048 modification Effects 0.000 claims 11
• 238000012986 modification Methods 0.000 claims 11
• 238000001727 in vivo Methods 0.000 claims 7
• 239000008188 pellet Substances 0.000 claims 7
• 239000002202 Polyethylene glycol Substances 0.000 claims 6
• 239000008194 pharmaceutical composition Substances 0.000 claims 6
• 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims 6
• 229920001223 polyethylene glycol Polymers 0.000 claims 6
• 239000004094 surface-active agent Substances 0.000 claims 5
• 238000002347 injection Methods 0.000 claims 4
• 239000007924 injection Substances 0.000 claims 4
• JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims 4
• 229920000747 poly(lactic acid) Polymers 0.000 claims 4
• JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 claims 3
• 239000000463 material Substances 0.000 claims 3
• 208000022873 Ocular disease Diseases 0.000 claims 2
• 239000004372 Polyvinyl alcohol Substances 0.000 claims 2
• 150000001875 compounds Chemical class 0.000 claims 2
• 239000003937 drug carrier Substances 0.000 claims 2
• 208000030533 eye disease Diseases 0.000 claims 2
• 235000014655 lactic acid Nutrition 0.000 claims 2
• 239000004310 lactic acid Substances 0.000 claims 2
• 229920002451 polyvinyl alcohol Polymers 0.000 claims 2
• 150000003839 salts Chemical class 0.000 claims 2
• 230000002459 sustained effect Effects 0.000 claims 2
• 239000002562 thickening agent Substances 0.000 claims 2
• 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 2
• 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 2
• 150000004917 tyrosine kinase inhibitor derivatives Chemical group 0.000 claims 2
• KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims 1
• TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical group O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 claims 1
• 229940122072 Carbonic anhydrase inhibitor Drugs 0.000 claims 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
• 208000010412 Glaucoma Diseases 0.000 claims 1
• 239000002147 L01XE04 - Sunitinib Substances 0.000 claims 1
• 229930195725 Mannitol Natural products 0.000 claims 1
• 239000004698 Polyethylene Substances 0.000 claims 1
• 229920002385 Sodium hyaluronate Polymers 0.000 claims 1
• 206010064930 age-related macular degeneration Diseases 0.000 claims 1
• 210000002159 anterior chamber Anatomy 0.000 claims 1
• 239000002876 beta blocker Substances 0.000 claims 1
• 239000003489 carbonate dehydratase inhibitor Substances 0.000 claims 1
• LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 1
• 125000003827 glycol group Chemical group 0.000 claims 1
• 229920002674 hyaluronan Polymers 0.000 claims 1
• 229960003160 hyaluronic acid Drugs 0.000 claims 1
• WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims 1
• 230000002757 inflammatory effect Effects 0.000 claims 1
• 208000002780 macular degeneration Diseases 0.000 claims 1
• 239000000594 mannitol Substances 0.000 claims 1
• 235000010355 mannitol Nutrition 0.000 claims 1
• LBWFXVZLPYTWQI-IPOVEDGCSA-N n-[2-(diethylamino)ethyl]-5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide;(2s)-2-hydroxybutanedioic acid Chemical group OC(=O)[C@@H](O)CC(O)=O.CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C LBWFXVZLPYTWQI-IPOVEDGCSA-N 0.000 claims 1
• -1 polyethylene Polymers 0.000 claims 1
• 229920000573 polyethylene Polymers 0.000 claims 1
• 239000004626 polylactic acid Substances 0.000 claims 1
• 229940010747 sodium hyaluronate Drugs 0.000 claims 1
• 229960001796 sunitinib Drugs 0.000 claims 1
• WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 claims 1
• 229960002812 sunitinib malate Drugs 0.000 claims 1
• 229960004605 timolol Drugs 0.000 claims 1
• 230000000007 visual effect Effects 0.000 claims 1
• 101000628535 Homo sapiens Metalloreductase STEAP2 Proteins 0.000 description 6
• 102100026711 Metalloreductase STEAP2 Human genes 0.000 description 6
• 239000003085 diluting agent Substances 0.000 description 2
• 229940117392 provisc Drugs 0.000 description 2
• 239000003795 chemical substances by application Substances 0.000 description 1
• 239000012895 dilution Substances 0.000 description 1
• 238000010790 dilution Methods 0.000 description 1
• 238000011534 incubation Methods 0.000 description 1
• 239000008154 viscoelastic solution Substances 0.000 description 1